Mark L. Levitt MD PhD is a Board Certified Medical Oncologist and Internist in the US, and Specialty Certified as an Oncologist (Medical and Radiation) and Internist in Israel — with an academic and industry career spanning over four decades.
Education & training
1974–1978 1978–1981
MD & PhD
Temple University School of Medicine, Philadelphia, PA
1981–1984
Medical Internship & Residency
Hahnemann University Hospital, Philadelphia, PA
1984–1987
Medical Oncology Fellowship
National Cancer Institute (NIH) — Navy Medical Oncology Branch, Bethesda, MD
Board certifications
Medical Oncology (ABIM)
United States — 1987
Internal Medicine (ABIM)
United States — 1985
Oncology (Medical & Radiation)
Israel Medical Association — 2001
Internal Medicine
Israel Medical Association — 2000
Academic career — United States
1987–1994
Assistant Professor of Medicine · Director, Lung Cancer Center
University of Pittsburgh School of Medicine & Pittsburgh Cancer Institute
1994–1998
Associate Professor · Director, Lung Cancer Program
Allegheny University of the Health Sciences / Allegheny Cancer Center
Career — Israel
1999–2018
Senior Oncologist · Head, Lung Cancer Unit · Director, Clinical Research
Institute of Oncology, Sheba Medical Center (Tel Aviv University affiliate)
2000–2006
Scientific/Medical Director
Massis Early Detection, Inc. (Era-Massis) — cancer early detection startup
Pharmaceutical industry leadership
2005–2006
Head of Oncology
Inotek Pharmaceutical Corp. — responsible for PARP inhibitor development, licensed to Genentech for up to $625M
2006–2009
Clinical Oncology Platform Leader, Innovative R&D
Teva Pharmaceuticals Industries, Ltd.
2009–2013
Head, Oncology Search & Evaluation · Global Business Development
Teva Pharmaceuticals — led clinical DD on Cephalon acquisition ($6.8B); led OncoGeneX licensing deal ($430M)
2013–Present
CEO
Levitt Oncology Associates, Ltd.
2017–Present
Chief Scientific Officer
RedHill BioPharma, Ltd. — responsible for clinical, preclinical, and research R&D
2015–Present
Scientific/Clinical Advisory Board · Board of Directors
EnGeneIC, Ltd.
Recognition & awards
2022
Outstanding Leadership Award
Health 2.0 Conference — Dubai, UAE
2023
Best Medical Oncology Consultancy — Middle East
GHP Biotech Awards
2023
Middle East's 10 Successful Magnetic Leaders Revamping Healthcare